Skip to main content
PMC home page
Journal of Virology logoLink to Journal of Virology
. 1997 Apr;71(4):2799–2809. doi: 10.1128/jvi.71.4.2799-2809.1997

Differential regulation of the antibody responses to Gag and Env proteins of human immunodeficiency virus type 1.

J M Binley 1, P J Klasse 1, Y Cao 1, I Jones 1, M Markowitz 1, D D Ho 1, J P Moore 1
PMCID: PMC191404  PMID: 9060635

Abstract

We have studied the antibody responses to Env and Gag antigens of human immunodeficiency virus type 1 (HIV-1) in several cohorts of HIV-1-infected individuals: long-term nonprogressors, progressors to disease, acute seroconvertors, and recipients of HIV-1 protease inhibitors. We conclude that the antibody responses to Env and Gag antigens are differentially regulated and that changes in the plasma viral load in the measurable range (500 to 10(8) RNA copies per ml) do not directly affect the antibody responses to these HIV-1 proteins. We provide quantitative estimates of HIV-1-specific immunoglobulin G concentrations in plasma, which can be in excess of 1 mg/ml for both anti-gp120 and anti-p24 once the immune response to HIV-1 has stabilized after seroconversion. We discuss the apparent paradox that the absence of anti-Gag antibodies (which have, at best, limited antiviral activity) is indicative of disease progression, while the retention of anti-Env antibodies (which do have antiviral activity) is of limited (or no) prognostic value. We show that the disappearance of anti-Gag antibodies during disease progression is highly unlikely to be due to immune complexing; instead, we believe that it reflects the loss of T-cell help that is more necessary for the anti-Gag than the anti-Env response.

Full Text

The Full Text of this article is available as a PDF (184.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ahmed R., Gray D. Immunological memory and protective immunity: understanding their relation. Science. 1996 Apr 5;272(5258):54–60. doi: 10.1126/science.272.5258.54. [DOI] [PubMed] [Google Scholar]
  2. Albert J., Abrahamsson B., Nagy K., Aurelius E., Gaines H., Nyström G., Fenyö E. M. Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera. AIDS. 1990 Feb;4(2):107–112. doi: 10.1097/00002030-199002000-00002. [DOI] [PubMed] [Google Scholar]
  3. Allan J. S., Coligan J. E., Barin F., McLane M. F., Sodroski J. G., Rosen C. A., Haseltine W. A., Lee T. H., Essex M. Major glycoprotein antigens that induce antibodies in AIDS patients are encoded by HTLV-III. Science. 1985 May 31;228(4703):1091–1094. doi: 10.1126/science.2986290. [DOI] [PubMed] [Google Scholar]
  4. Amadori A., De Rossi A., Faulkner-Valle G. P., Chieco-Bianchi L. Spontaneous in vitro production of virus-specific antibody by lymphocytes from HIV-infected subjects. Clin Immunol Immunopathol. 1988 Mar;46(3):342–351. doi: 10.1016/0090-1229(88)90053-0. [DOI] [PubMed] [Google Scholar]
  5. Amadori A., Zamarchi R., Ciminale V., Del Mistro A., Siervo S., Alberti A., Colombatti M., Chieco-Bianchi L. HIV-1-specific B cell activation. A major constituent of spontaneous B cell activation during HIV-1 infection. J Immunol. 1989 Oct 1;143(7):2146–2152. [PubMed] [Google Scholar]
  6. Andrieu J. M., Eme D., Venet A., Audroin C., Tourani J. M., Stern M., Israel-Biet D., Beldjord K., Driss F., Even P. Serum HIV antigen and anti-P24-antibodies in 200 HIV seropositive patients: correlation with CD4 and CD8 lymphocyte subsets. Clin Exp Immunol. 1988 Jul;73(1):1–5. [PMC free article] [PubMed] [Google Scholar]
  7. Arendrup M., Nielsen C., Hansen J. E., Pedersen C., Mathiesen L., Nielsen J. O. Autologous HIV-1 neutralizing antibodies: emergence of neutralization-resistant escape virus and subsequent development of escape virus neutralizing antibodies. J Acquir Immune Defic Syndr. 1992;5(3):303–307. [PubMed] [Google Scholar]
  8. Arendrup M., Sönnerborg A., Svennerholm B., Akerblom L., Nielsen C., Clausen H., Olofsson S., Nielsen J. O., Hansen J. E. Neutralizing antibody response during human immunodeficiency virus type 1 infection: type and group specificity and viral escape. J Gen Virol. 1993 May;74(Pt 5):855–863. doi: 10.1099/0022-1317-74-5-855. [DOI] [PubMed] [Google Scholar]
  9. Bachmann M. F., Kündig T. M., Kalberer C. P., Hengartner H., Zinkernagel R. M. How many specific B cells are needed to protect against a virus? J Immunol. 1994 May 1;152(9):4235–4241. [PubMed] [Google Scholar]
  10. Bachmann M. F., Rohrer U. H., Kündig T. M., Bürki K., Hengartner H., Zinkernagel R. M. The influence of antigen organization on B cell responsiveness. Science. 1993 Nov 26;262(5138):1448–1451. doi: 10.1126/science.8248784. [DOI] [PubMed] [Google Scholar]
  11. Barbas C. F., 3rd, Collet T. A., Amberg W., Roben P., Binley J. M., Hoekstra D., Cababa D., Jones T. M., Williamson R. A., Pilkington G. R. Molecular profile of an antibody response to HIV-1 as probed by combinatorial libraries. J Mol Biol. 1993 Apr 5;230(3):812–823. doi: 10.1006/jmbi.1993.1203. [DOI] [PubMed] [Google Scholar]
  12. Beckman E. M., Porcelli S. A., Morita C. T., Behar S. M., Furlong S. T., Brenner M. B. Recognition of a lipid antigen by CD1-restricted alpha beta+ T cells. Nature. 1994 Dec 15;372(6507):691–694. doi: 10.1038/372691a0. [DOI] [PubMed] [Google Scholar]
  13. Belec L., Jean Georges A., Hallouin M. C., Si Mohamed A., Morand-Joubert L., Georges-Courbot M. C. Human T-lymphotropic virus type I excretion and specific antibody response in paired saliva and cervicovaginal secretions. AIDS Res Hum Retroviruses. 1996 Jan 20;12(2):157–167. doi: 10.1089/aid.1996.12.157. [DOI] [PubMed] [Google Scholar]
  14. Belshe R. B., Graham B. S., Keefer M. C., Gorse G. J., Wright P., Dolin R., Matthews T., Weinhold K., Bolognesi D. P., Sposto R. Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. NIAID AIDS Vaccine Clinical Trials Network. JAMA. 1994 Aug 10;272(6):475–480. doi: 10.1001/jama.272.6.475. [DOI] [PubMed] [Google Scholar]
  15. Brown A. E., Vahey M. T., Zhou S. Y., Chung R. C., Ruiz N. M., Hofheinz D., Lane J. R., Mayers D. L. Quantitative relationship of circulating p24 antigen with human immunodeficiency virus (HIV) RNA and specific antibody in HIV-infected subjects receiving antiretroviral therapy. The RV43 Study Group. J Infect Dis. 1995 Oct;172(4):1091–1095. doi: 10.1093/infdis/172.4.1091. [DOI] [PubMed] [Google Scholar]
  16. Bélec L., Dupré T., Prazuck T., Tévi-Bénissan C., Kanga J. M., Pathey O., Lu X. S., Pillot J. Cervicovaginal overproduction of specific IgG to human immunodeficiency virus (HIV) contrasts with normal or impaired IgA local response in HIV infection. J Infect Dis. 1995 Sep;172(3):691–697. doi: 10.1093/infdis/172.3.691. [DOI] [PubMed] [Google Scholar]
  17. Cao Y., Ho D. D., Todd J., Kokka R., Urdea M., Lifson J. D., Piatak M., Jr, Chen S., Hahn B. H., Saag M. S. Clinical evaluation of branched DNA signal amplification for quantifying HIV type 1 in human plasma. AIDS Res Hum Retroviruses. 1995 Mar;11(3):353–361. doi: 10.1089/aid.1995.11.353. [DOI] [PubMed] [Google Scholar]
  18. Cao Y., Qin L., Zhang L., Safrit J., Ho D. D. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N Engl J Med. 1995 Jan 26;332(4):201–208. doi: 10.1056/NEJM199501263320401. [DOI] [PubMed] [Google Scholar]
  19. Castaño A. R., Tangri S., Miller J. E., Holcombe H. R., Jackson M. R., Huse W. D., Kronenberg M., Peterson P. A. Peptide binding and presentation by mouse CD1. Science. 1995 Jul 14;269(5221):223–226. doi: 10.1126/science.7542403. [DOI] [PubMed] [Google Scholar]
  20. Cheingsong-Popov R., Panagiotidi C., Bowcock S., Aronstam A., Wadsworth J., Weber J. Relation between humoral responses to HIV gag and env proteins at seroconversion and clinical outcome of HIV infection. BMJ. 1991 Jan 5;302(6767):23–26. doi: 10.1136/bmj.302.6767.23. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Conley A. J., Kessler J. A., 2nd, Boots L. J., McKenna P. M., Schleif W. A., Emini E. A., Mark G. E., 3rd, Katinger H., Cobb E. K., Lunceford S. M. The consequence of passive administration of an anti-human immunodeficiency virus type 1 neutralizing monoclonal antibody before challenge of chimpanzees with a primary virus isolate. J Virol. 1996 Oct;70(10):6751–6758. doi: 10.1128/jvi.70.10.6751-6758.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Connor R. I., Mohri H., Cao Y., Ho D. D. Increased viral burden and cytopathicity correlate temporally with CD4+ T-lymphocyte decline and clinical progression in human immunodeficiency virus type 1-infected individuals. J Virol. 1993 Apr;67(4):1772–1777. doi: 10.1128/jvi.67.4.1772-1777.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Doms R. W., Lamb R. A., Rose J. K., Helenius A. Folding and assembly of viral membrane proteins. Virology. 1993 Apr;193(2):545–562. doi: 10.1006/viro.1993.1164. [DOI] [PubMed] [Google Scholar]
  24. Embretson J., Zupancic M., Ribas J. L., Burke A., Racz P., Tenner-Racz K., Haase A. T. Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature. 1993 Mar 25;362(6418):359–362. doi: 10.1038/362359a0. [DOI] [PubMed] [Google Scholar]
  25. Fauci A. S. Multifactorial nature of human immunodeficiency virus disease: implications for therapy. Science. 1993 Nov 12;262(5136):1011–1018. doi: 10.1126/science.8235617. [DOI] [PubMed] [Google Scholar]
  26. Fenouillet E., Blanes N., Coutellier A., Demarquest J., Rozenbaum W., Gluckman J. C. Monitoring of antibodies against human immunodeficiency virus type 1 p25 core protein as prognostic marker. J Infect Dis. 1992 Sep;166(3):611–616. doi: 10.1093/infdis/166.3.611. [DOI] [PubMed] [Google Scholar]
  27. Fenouillet E., Blanes N., Coutellier A., Gluckman J. C. Relationship between anti-p24 antibody levels and p24 antigenemia in HIV-infected patients. AIDS Res Hum Retroviruses. 1993 Dec;9(12):1251–1255. doi: 10.1089/aid.1993.9.1251. [DOI] [PubMed] [Google Scholar]
  28. Fenouillet E., Gluckman J. C., Jones I. M. Functions of HIV envelope glycans. Trends Biochem Sci. 1994 Feb;19(2):65–70. doi: 10.1016/0968-0004(94)90034-5. [DOI] [PubMed] [Google Scholar]
  29. Gallaher W. R., Ball J. M., Garry R. F., Martin-Amedee A. M., Montelaro R. C. A general model for the surface glycoproteins of HIV and other retroviruses. AIDS Res Hum Retroviruses. 1995 Feb;11(2):191–202. doi: 10.1089/aid.1995.11.191. [DOI] [PubMed] [Google Scholar]
  30. Gelderblom H. R. Assembly and morphology of HIV: potential effect of structure on viral function. AIDS. 1991 Jun;5(6):617–637. [PubMed] [Google Scholar]
  31. Graham B. S., Wright P. F. Candidate AIDS vaccines. N Engl J Med. 1995 Nov 16;333(20):1331–1339. doi: 10.1056/NEJM199511163332007. [DOI] [PubMed] [Google Scholar]
  32. Gray D. Immunological memory. Annu Rev Immunol. 1993;11:49–77. doi: 10.1146/annurev.iy.11.040193.000405. [DOI] [PubMed] [Google Scholar]
  33. Groopman J. E., Benz P. M., Ferriani R., Mayer K., Allan J. D., Weymouth L. A. Characterization of serum neutralization response to the human immunodeficiency virus (HIV). AIDS Res Hum Retroviruses. 1987 Spring;3(1):71–85. doi: 10.1089/aid.1987.3.71. [DOI] [PubMed] [Google Scholar]
  34. Haase A. T., Henry K., Zupancic M., Sedgewick G., Faust R. A., Melroe H., Cavert W., Gebhard K., Staskus K., Zhang Z. Q. Quantitative image analysis of HIV-1 infection in lymphoid tissue. Science. 1996 Nov 8;274(5289):985–989. doi: 10.1126/science.274.5289.985. [DOI] [PubMed] [Google Scholar]
  35. Hariharan K., Nara P. L., Shabazz L. A., McCutchan J. A., Kang C. Y. Analysis of B cell repertoire specific to the neutralizing epitopes of glycoprotein 120 in HIV-infected individuals. AIDS Res Hum Retroviruses. 1994 Dec;10(12):1629–1637. doi: 10.1089/aid.1994.10.1629. [DOI] [PubMed] [Google Scholar]
  36. Harrer T., Harrer E., Kalams S. A., Elbeik T., Staprans S. I., Feinberg M. B., Cao Y., Ho D. D., Yilma T., Caliendo A. M. Strong cytotoxic T cell and weak neutralizing antibody responses in a subset of persons with stable nonprogressing HIV type 1 infection. AIDS Res Hum Retroviruses. 1996 May 1;12(7):585–592. doi: 10.1089/aid.1996.12.585. [DOI] [PubMed] [Google Scholar]
  37. Haynes B. F., Pantaleo G., Fauci A. S. Toward an understanding of the correlates of protective immunity to HIV infection. Science. 1996 Jan 19;271(5247):324–328. doi: 10.1126/science.271.5247.324. [DOI] [PubMed] [Google Scholar]
  38. Ho D. D., Neumann A. U., Perelson A. S., Chen W., Leonard J. M., Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature. 1995 Jan 12;373(6510):123–126. doi: 10.1038/373123a0. [DOI] [PubMed] [Google Scholar]
  39. Hogervorst E., Jurriaans S., de Wolf F., van Wijk A., Wiersma A., Valk M., Roos M., van Gemen B., Coutinho R., Miedema F. Predictors for non- and slow progression in human immunodeficiency virus (HIV) type 1 infection: low viral RNA copy numbers in serum and maintenance of high HIV-1 p24-specific but not V3-specific antibody levels. J Infect Dis. 1995 Apr;171(4):811–821. doi: 10.1093/infdis/171.4.811. [DOI] [PubMed] [Google Scholar]
  40. Inaba K., Steinman R. M., Van Voorhis W. C., Muramatsu S. Dendritic cells are critical accessory cells for thymus-dependent antibody responses in mouse and in man. Proc Natl Acad Sci U S A. 1983 Oct;80(19):6041–6045. doi: 10.1073/pnas.80.19.6041. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Jiang W., Swiggard W. J., Heufler C., Peng M., Mirza A., Steinman R. M., Nussenzweig M. C. The receptor DEC-205 expressed by dendritic cells and thymic epithelial cells is involved in antigen processing. Nature. 1995 May 11;375(6527):151–155. doi: 10.1038/375151a0. [DOI] [PubMed] [Google Scholar]
  42. Kelleher A. D., Carr A., Zaunders J., Cooper D. A. Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir. J Infect Dis. 1996 Feb;173(2):321–329. doi: 10.1093/infdis/173.2.321. [DOI] [PubMed] [Google Scholar]
  43. Kishimoto T., Hirano T. Molecular regulation of B lymphocyte response. Annu Rev Immunol. 1988;6:485–512. doi: 10.1146/annurev.iy.06.040188.002413. [DOI] [PubMed] [Google Scholar]
  44. Klasse P. J., Moore J. P. Quantitative model of antibody- and soluble CD4-mediated neutralization of primary isolates and T-cell line-adapted strains of human immunodeficiency virus type 1. J Virol. 1996 Jun;70(6):3668–3677. doi: 10.1128/jvi.70.6.3668-3677.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Klasse P. J., Sattentau Q. J. Altered CD4 interactions of HIV type 1 LAI variants selected for the capacity to induce membrane fusion in the presence of a monoclonal antibody to domain 2 of CD4. AIDS Res Hum Retroviruses. 1996 Jul 20;12(11):1015–1021. doi: 10.1089/aid.1996.12.1015. [DOI] [PubMed] [Google Scholar]
  46. Koup R. A., Safrit J. T., Cao Y., Andrews C. A., McLeod G., Borkowsky W., Farthing C., Ho D. D. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol. 1994 Jul;68(7):4650–4655. doi: 10.1128/jvi.68.7.4650-4655.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Lange J. M., Paul D. A., de Wolf F., Coutinho R. A., Goudsmit J. Viral gene expression, antibody production and immune complex formation in human immunodeficiency virus infection. AIDS. 1987 May;1(1):15–20. [PubMed] [Google Scholar]
  48. Lanzavecchia A. Antigen uptake and accumulation in antigen-specific B cells. Immunol Rev. 1987 Oct;99:39–51. doi: 10.1111/j.1600-065x.1987.tb01171.x. [DOI] [PubMed] [Google Scholar]
  49. Lanzavecchia A. Antigen-specific interaction between T and B cells. Nature. 1985 Apr 11;314(6011):537–539. doi: 10.1038/314537a0. [DOI] [PubMed] [Google Scholar]
  50. Lanzavecchia A., Bove S. Specific B lymphocytes efficiently pick up, process and present antigen to T cells. Behring Inst Mitt. 1985 Aug;(77):82–87. [PubMed] [Google Scholar]
  51. Lanzavecchia A., Roosnek E., Gregory T., Berman P., Abrignani S. T cells can present antigens such as HIV gp120 targeted to their own surface molecules. Nature. 1988 Aug 11;334(6182):530–532. doi: 10.1038/334530a0. [DOI] [PubMed] [Google Scholar]
  52. Leonard C. K., Spellman M. W., Riddle L., Harris R. J., Thomas J. N., Gregory T. J. Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. J Biol Chem. 1990 Jun 25;265(18):10373–10382. [PubMed] [Google Scholar]
  53. Martin-Rico P., Pedersen C., Skinhøj P., Nielsen C., Lindhardt B. O. Rapid development of AIDS in an HIV-1-antibody-negative homosexual man. AIDS. 1995 Jan;9(1):95–96. [PubMed] [Google Scholar]
  54. Mascola J. R., Snyder S. W., Weislow O. S., Belay S. M., Belshe R. B., Schwartz D. H., Clements M. L., Dolin R., Graham B. S., Gorse G. J. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. J Infect Dis. 1996 Feb;173(2):340–348. doi: 10.1093/infdis/173.2.340. [DOI] [PubMed] [Google Scholar]
  55. Matzinger P. Immunology. Memories are made of this? Nature. 1994 Jun 23;369(6482):605–606. doi: 10.1038/369605a0. [DOI] [PubMed] [Google Scholar]
  56. McDougal J. S., Kennedy M. S., Orloff S. L., Nicholson J. K., Spira T. J. Mechanisms of human immunodeficiency virus Type 1 (HIV-1) neutralization: irreversible inactivation of infectivity by anti-HIV-1 antibody. J Virol. 1996 Aug;70(8):5236–5245. doi: 10.1128/jvi.70.8.5236-5245.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. McKeating J. A., McKnight A., Moore J. P. Differential loss of envelope glycoprotein gp120 from virions of human immunodeficiency virus type 1 isolates: effects on infectivity and neutralization. J Virol. 1991 Feb;65(2):852–860. doi: 10.1128/jvi.65.2.852-860.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. Mizuma H., Litwin S., Zolla-Pazner S. B-cell activation in HIV infection: relationship of spontaneous immunoglobulin secretion to various immunological parameters. Clin Exp Immunol. 1988 Mar;71(3):410–416. [PMC free article] [PubMed] [Google Scholar]
  59. Montefiori D. C., Pantaleo G., Fink L. M., Zhou J. T., Zhou J. Y., Bilska M., Miralles G. D., Fauci A. S. Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors. J Infect Dis. 1996 Jan;173(1):60–67. doi: 10.1093/infdis/173.1.60. [DOI] [PubMed] [Google Scholar]
  60. Montefiori D. C., Zhou I. Y., Barnes B., Lake D., Hersh E. M., Masuho Y., Lefkowitz L. B., Jr Homotypic antibody responses to fresh clinical isolates of human immunodeficiency virus. Virology. 1991 Jun;182(2):635–643. doi: 10.1016/0042-6822(91)90604-a. [DOI] [PubMed] [Google Scholar]
  61. Moore J. P., Cao Y., Ho D. D., Koup R. A. Development of the anti-gp120 antibody response during seroconversion to human immunodeficiency virus type 1. J Virol. 1994 Aug;68(8):5142–5155. doi: 10.1128/jvi.68.8.5142-5155.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Moore J. P., Cao Y., Leu J., Qin L., Korber B., Ho D. D. Inter- and intraclade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes. J Virol. 1996 Jan;70(1):427–444. doi: 10.1128/jvi.70.1.427-444.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  63. Moore J. P., Cao Y., Qing L., Sattentau Q. J., Pyati J., Koduri R., Robinson J., Barbas C. F., 3rd, Burton D. R., Ho D. D. Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120. J Virol. 1995 Jan;69(1):101–109. doi: 10.1128/jvi.69.1.101-109.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  64. Moore J. P., Ho D. D. HIV-1 neutralization: the consequences of viral adaptation to growth on transformed T cells. AIDS. 1995;9 (Suppl A):S117–S136. [PubMed] [Google Scholar]
  65. Moore J. P., Sodroski J. Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein. J Virol. 1996 Mar;70(3):1863–1872. doi: 10.1128/jvi.70.3.1863-1872.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  66. Morrow W. J., Wharton M., Stricker R. B., Levy J. A. Circulating immune complexes in patients with acquired immune deficiency syndrome contain the AIDS-associated retrovirus. Clin Immunol Immunopathol. 1986 Sep;40(3):515–524. doi: 10.1016/0090-1229(86)90196-0. [DOI] [PubMed] [Google Scholar]
  67. Norley S., Beer B., Binninger-Schinzel D., Cosma C., Kurth R. Protection from pathogenic SIVmac challenge following short-term infection with a nef-deficient attenuated virus. Virology. 1996 May 1;219(1):195–205. doi: 10.1006/viro.1996.0237. [DOI] [PubMed] [Google Scholar]
  68. Oka S., Ida S., Shioda T., Takebe Y., Kobayashi N., Shibuya Y., Ohyama K., Momota K., Kimura S., Shimada K. Genetic analysis of HIV-1 during rapid progression to AIDS in an apparently healthy man. AIDS Res Hum Retroviruses. 1994 Mar;10(3):271–277. doi: 10.1089/aid.1994.10.271. [DOI] [PubMed] [Google Scholar]
  69. Pahwa S., Pahwa R., Good R. A., Gallo R. C., Saxinger C. Stimulatory and inhibitory influences of human immunodeficiency virus on normal B lymphocytes. Proc Natl Acad Sci U S A. 1986 Dec;83(23):9124–9128. doi: 10.1073/pnas.83.23.9124. [DOI] [PMC free article] [PubMed] [Google Scholar]
  70. Pantaleo G., Graziosi C., Demarest J. F., Butini L., Montroni M., Fox C. H., Orenstein J. M., Kotler D. P., Fauci A. S. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature. 1993 Mar 25;362(6418):355–358. doi: 10.1038/362355a0. [DOI] [PubMed] [Google Scholar]
  71. Perelson A. S., Neumann A. U., Markowitz M., Leonard J. M., Ho D. D. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science. 1996 Mar 15;271(5255):1582–1586. doi: 10.1126/science.271.5255.1582. [DOI] [PubMed] [Google Scholar]
  72. Porcelli S., Morita C. T., Brenner M. B. CD1b restricts the response of human CD4-8- T lymphocytes to a microbial antigen. Nature. 1992 Dec 10;360(6404):593–597. doi: 10.1038/360593a0. [DOI] [PubMed] [Google Scholar]
  73. Robey W. G., Safai B., Oroszlan S., Arthur L. O., Gonda M. A., Gallo R. C., Fischinger P. J. Characterization of envelope and core structural gene products of HTLV-III with sera from AIDS patients. Science. 1985 May 3;228(4699):593–595. doi: 10.1126/science.2984774. [DOI] [PubMed] [Google Scholar]
  74. Sallusto F., Cella M., Danieli C., Lanzavecchia A. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J Exp Med. 1995 Aug 1;182(2):389–400. doi: 10.1084/jem.182.2.389. [DOI] [PMC free article] [PubMed] [Google Scholar]
  75. Sattentau Q. J., Weiss R. A. The CD4 antigen: physiological ligand and HIV receptor. Cell. 1988 Mar 11;52(5):631–633. doi: 10.1016/0092-8674(88)90397-2. [DOI] [PubMed] [Google Scholar]
  76. Schmidt G., Amiraian K., Frey H., Wethers J., Stevens R. W., Berns D. S. Monitoring human immunodeficiency virus type 1-infected patients by ratio of antibodies to gp41 and p24. J Clin Microbiol. 1989 May;27(5):843–848. doi: 10.1128/jcm.27.5.843-848.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  77. Schwartz D. H., Cosentino L. M., Shirai A., Conover J., Daniel S., Klinman D. M. Lack of correlation between the number of circulating B cells and the concentration of serum antibodies reactive with the HIV-1 envelope glycoprotein. J Acquir Immune Defic Syndr. 1994 May;7(5):447–453. [PubMed] [Google Scholar]
  78. Sheppard H. W., Ascher M. S., McRae B., Anderson R. E., Lang W., Allain J. P. The initial immune response to HIV and immune system activation determine the outcome of HIV disease. J Acquir Immune Defic Syndr. 1991;4(7):704–712. [PubMed] [Google Scholar]
  79. Shirai A., Cosentino M., Leitman-Klinman S. F., Klinman D. M. Human immunodeficiency virus infection induces both polyclonal and virus-specific B cell activation. J Clin Invest. 1992 Feb;89(2):561–566. doi: 10.1172/JCI115621. [DOI] [PMC free article] [PubMed] [Google Scholar]
  80. Sieling P. A., Chatterjee D., Porcelli S. A., Prigozy T. I., Mazzaccaro R. J., Soriano T., Bloom B. R., Brenner M. B., Kronenberg M., Brennan P. J. CD1-restricted T cell recognition of microbial lipoglycan antigens. Science. 1995 Jul 14;269(5221):227–230. doi: 10.1126/science.7542404. [DOI] [PubMed] [Google Scholar]
  81. Slifka M. K., Matloubian M., Ahmed R. Bone marrow is a major site of long-term antibody production after acute viral infection. J Virol. 1995 Mar;69(3):1895–1902. doi: 10.1128/jvi.69.3.1895-1902.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  82. Soriano V., Dronda F., González-López A., Chaves F., Bravo R., Gutiérrez M., Heredia A., Hewlett I. HIV-1 causing AIDS and death in a seronegative individual. Vox Sang. 1994;67(4):410–411. doi: 10.1111/j.1423-0410.1994.tb01286.x. [DOI] [PubMed] [Google Scholar]
  83. Strathdee S. A., Frank J. W., McLaughlin J., Leblanc M., Major C., O'Shaughnessy M. V., Read S. E. Quantitative measures of human immunodeficiency virus-specific antibodies predict progression to AIDS. J Infect Dis. 1995 Nov;172(5):1375–1379. doi: 10.1093/infdis/172.5.1375. [DOI] [PubMed] [Google Scholar]
  84. Szomolanyi-Tsuda E., Welsh R. M. T cell-independent antibody-mediated clearance of polyoma virus in T cell-deficient mice. J Exp Med. 1996 Feb 1;183(2):403–411. doi: 10.1084/jem.183.2.403. [DOI] [PMC free article] [PubMed] [Google Scholar]
  85. Teeuwsen V. J., Lange J. M., Keet R., Schattenkerk J. K., Debouck C., van den Akker R., Goudsmit J., Osterhaus A. D. Low number of functionally active B lymphocytes in the peripheral blood of HIV-1-seropositive individuals with low p24-specific serum antibody titers. AIDS. 1991 Aug;5(8):971–979. doi: 10.1097/00002030-199108000-00008. [DOI] [PubMed] [Google Scholar]
  86. Trauger R. J., Ferre F., Daigle A. E., Jensen F. C., Moss R. B., Mueller S. H., Richieri S. P., Slade H. B., Carlo D. J. Effect of immunization with inactivated gp120-depleted human immunodeficiency virus type 1 (HIV-1) immunogen on HIV-1 immunity, viral DNA, and percentage of CD4 cells. J Infect Dis. 1994 Jun;169(6):1256–1264. doi: 10.1093/infdis/169.6.1256. [DOI] [PubMed] [Google Scholar]
  87. Tremblay M., Wainberg M. A. Neutralization of multiple HIV-1 isolates from a single subject by autologous sequential sera. J Infect Dis. 1990 Sep;162(3):735–737. doi: 10.1093/infdis/162.3.735. [DOI] [PubMed] [Google Scholar]
  88. Tsang M. L., Evans L. A., McQueen P., Hurren L., Byrne C., Penny R., Tindall B., Cooper D. A. Neutralizing antibodies against sequential autologous human immunodeficiency virus type 1 isolates after seroconversion. J Infect Dis. 1994 Nov;170(5):1141–1147. doi: 10.1093/infdis/170.5.1141. [DOI] [PubMed] [Google Scholar]
  89. Vallejo A., Bravo R., Heredia A., Soriano V., Dronda F., Hewlett I. K. Sequence analysis of the V1/V2 and V3 domains in an HIV-seronegative AIDS patient. AIDS Res Hum Retroviruses. 1995 Dec;11(12):1539–1541. doi: 10.1089/aid.1995.11.1539. [DOI] [PubMed] [Google Scholar]
  90. Veenstra J., Williams I. G., Colebunders R., Dorrell L., Tchamouroff S. E., Patou G., Lange J. M., Weller I. V., Goeman J., Uthayakumar S. Immunization with recombinant p17/p24:Ty virus-like particles in human immunodeficiency virus-infected persons. J Infect Dis. 1996 Oct;174(4):862–866. doi: 10.1093/infdis/174.4.862. [DOI] [PubMed] [Google Scholar]
  91. Vogel T., Kurth R., Norley S. The majority of neutralizing Abs in HIV-1-infected patients recognize linear V3 loop sequences. Studies using HIV-1MN multiple antigenic peptides. J Immunol. 1994 Aug 15;153(4):1895–1904. [PubMed] [Google Scholar]
  92. Von Gegerfelt A., Albert J., Morfeldt-Månson L., Broliden K., Fenyö E. M. Isolate-specific neutralizing antibodies in patients with progressive HIV-1-related disease. Virology. 1991 Nov;185(1):162–168. doi: 10.1016/0042-6822(91)90764-3. [DOI] [PubMed] [Google Scholar]
  93. Wei X., Ghosh S. K., Taylor M. E., Johnson V. A., Emini E. A., Deutsch P., Lifson J. D., Bonhoeffer S., Nowak M. A., Hahn B. H. Viral dynamics in human immunodeficiency virus type 1 infection. Nature. 1995 Jan 12;373(6510):117–122. doi: 10.1038/373117a0. [DOI] [PubMed] [Google Scholar]
  94. Wen L., Roberts S. J., Viney J. L., Wong F. S., Mallick C., Findly R. C., Peng Q., Craft J. E., Owen M. J., Hayday A. C. Immunoglobulin synthesis and generalized autoimmunity in mice congenitally deficient in alpha beta(+) T cells. Nature. 1994 Jun 23;369(6482):654–658. doi: 10.1038/369654a0. [DOI] [PubMed] [Google Scholar]
  95. Wendler I., Bienzle U., Hunsmann G. Neutralizing antibodies and the course of HIV-induced disease. AIDS Res Hum Retroviruses. 1987 Summer;3(2):157–163. doi: 10.1089/aid.1987.3.157. [DOI] [PubMed] [Google Scholar]
  96. Zwart G., van der Hoek L., Valk M., Cornelissen M. T., Baan E., Dekker J., Koot M., Kuiken C. L., Goudsmit J. Antibody responses to HIV-1 envelope and gag epitopes in HIV-1 seroconverters with rapid versus slow disease progression. Virology. 1994 Jun;201(2):285–293. doi: 10.1006/viro.1994.1293. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Virology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES